Legal & General Group
MLNT

Legal & General Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Legal & General Group’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,058
Closed -$7K – 3473
2019
Q2 		$7K Hold
1,058
– – ﹤0.01% 3426
2019
Q1 		$4K Sell
1,058
-1
-0.1% -$5 ﹤0.01% 3327
2018
Q4 		$4K Hold
1,059
– – ﹤0.01% 3361
2018
Q3 		$21K Buy
1,059
+530
+100% +$13.4K ﹤0.01% 3196
2018
Q2 		$17K Hold
529
– – ﹤0.01% 3230
2018
Q1 		$20K Sell
529
-15
-3% -$986 ﹤0.01% 3118
2017
Q4 		$43K Buy
+544
New +$40.3K ﹤0.01% 2926

Other funds holding MLNT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Legal & General Group's MLNT Position: Q3 2019 in Review

Legal & General Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 1,058 shares — an estimated $7K sold.

Legal & General Group first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $43K in Q4 2017. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

  • Legal & General Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Legal & General Group sold 1,058 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $7K.
  • Legal & General Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
  • Legal & General Group's Melinta Therapeutics, Inc. Common Stock position peaked at $43K in Q4 2017.
  • 47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Legal & General Group's 13F filing for Q3 2019, filed 13 Nov 2019.